Clinical

These findings from research into diffuse large B cell lymphoma (DLBCL) are based on analyses of human patients and a murine model.

A discussion surrounding clinical trials in multiple sclerosis is led by Dr Haumschild.

The panel expands on the role of BTK inhibitors in the MS treatment landscape.

The patient in this case experienced significant muscle weakness after emerging from anesthesia.

Investigators said it is important for clinicians to interpret scans with knowledge of case-specific context for patients with diffuse large B-cell lymphoma (DLBCL).

Noortje van Herwaarden, MD, PhD, discusses the results of a 10-year follow-up from the DRESS study and how it informs use of disease activity-guided dose optimization in treatment of rheumatoid arthritis.

Ropeginterferon alfa-2b was moved to preferred status for patients with high- and low-risk polycythemia vera in a recent update to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology.

Recent developments in nanoparticle-mediated cancer immunotherapy promote treatment with less toxicity.

The panel discusses unmet needs that remain in the treatment and management of HIV.

Dr Welch leads a discussion on collaborations between payers, patients, and providers to optimize the care of patients with HIV.

In their closing thoughts, the panelists provide their key takeaways regarding immunizing against RSV.

Artificial intelligence may be leveraged to improve minimal residual disease measurements for patients.

Serial biopsies help explain why patients with late relapses of diffuse large B-cell lymphoma (DLBCL) fare better than those with early relapses.

BTK inhibitor implementation for MS treatment is explored.

The panelists provide insights into the decision-making process behind switching MS treatment strategies due to lacking or failed therapies.

Outcomes for patients with this form of the disease are poor and treatment options are limited.

Measurable residual disease (MRD) can predict disease progression in patients who have acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and chronic myeloid leukemia (CML).

This retrospective study showed that anti–interleukin-17 drug secukinumab yielded favorable results in a small group of patients with severe hidradenitis suppurativa (HS).

There are several reasons patients with multiple myeloma may experience the electrolyte abnormality.

Authors suggest the finding may indicate the cells play a role in hematological malignancies.

The Mayo Clinic’s Program for Rare and Undiagnosed Diseases was first implemented in 2018.

There are various immunotherapies being used in the second ling for patients with lymphomas, some of which have curative potential, explained Christopher Flowers, MD, MS, of the University of Texas MD Anderson Cancer Center.

Key opinion leaders discuss the value of real-world evidence in the management of HIV.

Assessing the quality of an HIV treatment plan is crucial to patient prognosis.

The therapy is still not widely used among older patients who have diffuse large B-cell lymphoma (DLBCL).

The treatment is the first approved by the FDA to treat the 2 most common subtypes of generalized myasthenia gravis.

In her closing thoughts, Dr Filer provides insights into the unmet needs in the treatment of RSV.

Discussion surrounding promotion of RSV vaccine awareness is further discussed.

The panel offers strategies for being proactive .

Investigators say their data show the importance of vaccination and antibiotic stewardship programs.